Spinraza denied as non-formulary by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Spinraza as Non-Formulary

Spinraza (nusinersen) is a high-cost specialty biologic administered intrathecally by a specialist. Aetna's formulary placement — or exclusion — is a plan-design decision that can vary by employer group, plan year, and plan type. A non-formulary denial means Spinraza is not on the tier structure that your specific plan covers, or is not covered at all under the plan's drug benefit.

Non-formulary denials for disease-modifying therapies in serious conditions like spinal muscular atrophy are among the most commonly overturned on appeal, because the medical-necessity argument is often compelling and because Aetna's own formulary exception process is designed for exactly this situation.

## Federal Appeal Rights

• Formulary exception process: Before or alongside a formal appeal, request a formulary exception. Aetna is required under ACA regulations to have a formulary exception process, and must grant an exception when there is no therapeutically equivalent covered alternative or when the covered alternative is contraindicated or would be ineffective for the patient.
• ACA §2719 external review: If the formulary exception is denied, you have the right to external review. The approximately four-month window runs from the denial of the exception or the coverage denial.
• ERISA §503: Employer-plan members have full internal appeal rights, including the right to see exactly why the formulary exception was denied.
• Expedited review: Request expedited processing given the progressive nature of SMA.

## Documentation to Gather

• No adequate alternative: A letter from the prescribing neuromuscular specialist explaining that any formulary-covered SMA therapy is not clinically equivalent or appropriate for this patient, with specific clinical reasoning (not just preference).
• Diagnosis and SMA type: Genetic confirmation and clinical documentation of SMA type, functional status, and disease course.
• Prior therapy documentation: If a formulary alternative was previously tried and failed, document dates, doses, and outcomes in detail.
• Contraindication or inadequacy documentation: If a covered formulary alternative is medically inappropriate, the prescriber's documented rationale explaining why.
• Medical-necessity letter: A formal letter from the specialist addressing Aetna's formulary exception criteria directly.

## Criteria-Mapping Framework

Request Aetna's formulary exception criteria in writing. Most formulary exception processes require showing one or more of the following — map your case to each:

| Exception Criterion | Patient Evidence | |---|---| | No formulary-covered therapeutically equivalent alternative exists | Specialist letter explaining clinical distinction | | Formulary alternative is contraindicated or ineffective for this patient | Chart documentation + prescriber explanation | | Medical necessity for the non-formulary drug specifically | Genetic report + functional assessment + specialist letter |

If Aetna's plan has no covered SMA therapy at all, the appeal should argue that the plan's exclusion is discriminatory toward patients with a specific medical condition and request external review on that basis.